Recent advances in lean NAFLD - 31/08/22
, Yanqi Dang a, ⁎ Abstract |
As the predominant type of chronic liver disease, the growing prevalence of nonalcoholic fatty liver disease (NAFLD) has become a concern worldwide. Although obesity plays the most pivotal role in NAFLD, approximately 10–20% of individuals with NAFLD who are not overweight or obese (BMI < 25 kg/m2, or BMI < 23 kg/m2 in Asians) have “lean NAFLD.” Lean individuals with NAFLD have a lower prevalence of diabetes, hypertension, hypertriglyceridemia, central obesity, and metabolic syndrome than nonlean individuals with NAFLD, but higher fibrosis scores and rates of cardiovascular morbidity and all-cause mortality in advanced stages. The pathophysiological mechanisms of lean NAFLD remain poorly understood. Studies have shown that lean NAFLD is more correlated with factors such as environmental, genetic susceptibility, and epigenetic regulation. This review will examine the way in which the research progress and characteristic of lean NAFLD, and explore the function of epigenetic modification to provide the basis for the clinical treatment and diagnosis of lean NAFLD.
Il testo completo di questo articolo è disponibile in PDF.Graphical Abstract |
Highlights |
• | Approximately 10–20% of individuals with NAFLD have “lean NAFLD.” |
• | Lean individuals with NAFLD have a lower prevalence of diabetes, hypertension, hypertriglyceridemia, obesity, and metabolic syndrome, but higher fibrosis scores and rates of cardiovascular morbidity and all-cause mortality in advanced stages. |
• | Lean NAFLD is categorized into two broad subtypes based on epidemiology, natural history, and prognosis. |
• | The progression of lean NAFLD is affected by multiple epigenetic mechanisms. |
• | The development of an improved non-invasive assessment and animal models of lean NAFLD are urgent. |
Keywords : Lean nonalcoholic fatty liver disease, Metabolic risk, Delineation, Animal models, Epigenetic
Mappa
Vol 153
Articolo 113331- settembre 2022 Ritorno al numero
Articolo precedente
- Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma
- Jiaqi Sheng, Enjun Lv, Limin Xia, Wenjie Huang
- Gene therapy clinical trials, where do we go? An overview
- Fatemeh Arabi, Vahid Mansouri, Naser Ahmadbeigi
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?